Courageous. Focused. Passionate.

Pioneering Development of Life-Changing Treatments by Leveraging the Untapped Mechanisms of the Lysosome

Diseases for which medicine offers few effective options-advanced cancer, neurodegenerative diseases, lysosomal storage diseases and autoimmune diseases-persist because they involve very complex and interrelated cellular operations. Bexion is committed to unlocking the workings of the lysosome, the key cellular orchestrator, to provide patients effective, non-toxic therapies where none currently exist.

banner-info
Home2021-09-10T08:00:30-04:00
Watch the video

– WATCH

Bexion Pharmaceuticals President & CEO Ray Takigiku featured on ADVANCEMENTS TV with Ted Danson

In this episode, Advancements will explore how lysosomes play a role in a broad range of diseases including cancer, Alzheimer’s, Parkinson’s, and even infectious diseases such as viruses and bacteria. Hearing from experts in the field, audiences will discover how Bexion Pharmaceuticals, Inc. (Bexion) – a clinical stage biotech company– is leveraging the lysosome’s role to treat even very advanced cancers and improve patient’s quality of life.

– Our Platform

An innovative, targeted approach to treating cancer

For the last 20 years since the mapping of the human genome, many cancer therapeutics have targeted cellular mutations and not the cancer cells’ environment.

By utilizing a small lysosomal protein known as Saposin C our approach specifically targets unique features of cancer cells and their environment, including externalized phosphatidylserine and tumor cell lysosomes.

Learn More

– Our Pipeline

A Pipeline-in-a-Product asset with potential for multiple indications

BXQ-350 is the foundation of our pipeline. Early clinical results have shown a strong safety and tolerability profile.

Learn More

– clinical trials

Update

Our clinical trials are regulated by the Food and Drug Administration (FDA) in the United States and by similar regulatory agencies worldwide.

Learn More

Resources

Bexion Resources

Resources

Learn More
View All Resources

News

    Press Release

    Bexion Pharmaceuticals, Inc. to Present at the 2021 Discovery on Target Conference

    September 17, 2021

    FOR IMMEDIATE RELEASE [Covington, KY---September 17, 2021] Bexion Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, announced today that Gilles Tapolsky PhD, MBA, Bexion’s Vice President, Pharmacology will be virtually presenting preclinical and clinical data of the Company’s lead compound, BXQ-350.  The presentation will be made at the Discovery on Target (DOT) Conference in the Immunology and ... Read More

      Press Release

      Bexion Pharmaceuticals, Inc. to Present at the 2021 Association for Cancer Immunotherapy (CIMT) Annual Meeting

      April 20, 2021

      FOR IMMEDIATE RELEASE [Covington, KY---April 20, 2021] Bexion Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, announced today that an abstract submitted for an eTalk Session at the CIMT annual meeting to be held virtually May 10-12, 2021 has been chosen for presentation. Every year, the CIMT Annual Meeting connects the global cancer immunotherapy community in the ... Read More

      View All Media